Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. / Kissow, Hannelouise; Viby, Niels-Erik; Hartmann, Bolette; Holst, Jens Juul; Timm, Michael; Thim, Lars; Poulsen, Steen Seier.

In: Cancer Chemotherapy and Pharmacology. Supplement, Vol. 70, No. 1, 2012, p. 39-48.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kissow, H, Viby, N-E, Hartmann, B, Holst, JJ, Timm, M, Thim, L & Poulsen, SS 2012, 'Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine', Cancer Chemotherapy and Pharmacology. Supplement, vol. 70, no. 1, pp. 39-48. https://doi.org/10.1007/s00280-012-1882-2

APA

Kissow, H., Viby, N-E., Hartmann, B., Holst, J. J., Timm, M., Thim, L., & Poulsen, S. S. (2012). Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. Cancer Chemotherapy and Pharmacology. Supplement, 70(1), 39-48. https://doi.org/10.1007/s00280-012-1882-2

Vancouver

Kissow H, Viby N-E, Hartmann B, Holst JJ, Timm M, Thim L et al. Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. Cancer Chemotherapy and Pharmacology. Supplement. 2012;70(1):39-48. https://doi.org/10.1007/s00280-012-1882-2

Author

Kissow, Hannelouise ; Viby, Niels-Erik ; Hartmann, Bolette ; Holst, Jens Juul ; Timm, Michael ; Thim, Lars ; Poulsen, Steen Seier. / Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. In: Cancer Chemotherapy and Pharmacology. Supplement. 2012 ; Vol. 70, No. 1. pp. 39-48.

Bibtex

@article{6f9b24e384804e9d814135da28874141,
title = "Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine",
abstract = "PURPOSE: Gastrointestinal mucositis is an unwanted and often dose-limiting side effect to most cancer treatments. Glucagon-like peptide-2 (GLP-2) is a peptide secreted from intestinal L-cells in response to nutrient intake. The peptide is involved in the regulation of apoptosis and proliferation in the intestine. We aimed to investigate the role of GLP-2 in experimental chemotherapy-induced mucositis. METHODS STUDY 1: Rats were given a single injection with 5-fluorouracil (5-FU) and killed in groups of five each day for 5 days. Blood samples were analysed for GLP-2 concentrations. The intestine was analysed for weight loss, morphometric estimates and proliferation. Study 2 Rats were treated with GLP-2 or control vehicle 2 days before a single injection of 5-FU or saline. The treatments continued until kill 2 days after. The intestine was investigated for influx of myeloperoxidase (MPO)-positive cells and morphometric estimates, such as villus height, as a marker of mucositis. RESULTS STUDY 1: Two days after chemotherapy, there was a rise in endogenous GLP-2, followed by a marked increase in proliferation. Study 2 Exogenous GLP-2 was able to protect the intestine from severe weight loss and completely prevented the reduction in villus height in the control rats. Furthermore, there was a significant decrease in influx of MPO-positive cells in the GLP-2-treated rats. CONCLUSION: GLP-2 is secreted from the intestine in response to intestinal injury, probably explaining the compensatory hyperproliferation after chemotherapy. Exogenous GLP-2 can protect the mucosa from chemotherapy-induced mucositis in rats.",
author = "Hannelouise Kissow and Niels-Erik Viby and Bolette Hartmann and Holst, {Jens Juul} and Michael Timm and Lars Thim and Poulsen, {Steen Seier}",
year = "2012",
doi = "10.1007/s00280-012-1882-2",
language = "English",
volume = "70",
pages = "39--48",
journal = "Cancer Chemotherapy and Pharmacology. Supplement",
issn = "0943-9404",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine

AU - Kissow, Hannelouise

AU - Viby, Niels-Erik

AU - Hartmann, Bolette

AU - Holst, Jens Juul

AU - Timm, Michael

AU - Thim, Lars

AU - Poulsen, Steen Seier

PY - 2012

Y1 - 2012

N2 - PURPOSE: Gastrointestinal mucositis is an unwanted and often dose-limiting side effect to most cancer treatments. Glucagon-like peptide-2 (GLP-2) is a peptide secreted from intestinal L-cells in response to nutrient intake. The peptide is involved in the regulation of apoptosis and proliferation in the intestine. We aimed to investigate the role of GLP-2 in experimental chemotherapy-induced mucositis. METHODS STUDY 1: Rats were given a single injection with 5-fluorouracil (5-FU) and killed in groups of five each day for 5 days. Blood samples were analysed for GLP-2 concentrations. The intestine was analysed for weight loss, morphometric estimates and proliferation. Study 2 Rats were treated with GLP-2 or control vehicle 2 days before a single injection of 5-FU or saline. The treatments continued until kill 2 days after. The intestine was investigated for influx of myeloperoxidase (MPO)-positive cells and morphometric estimates, such as villus height, as a marker of mucositis. RESULTS STUDY 1: Two days after chemotherapy, there was a rise in endogenous GLP-2, followed by a marked increase in proliferation. Study 2 Exogenous GLP-2 was able to protect the intestine from severe weight loss and completely prevented the reduction in villus height in the control rats. Furthermore, there was a significant decrease in influx of MPO-positive cells in the GLP-2-treated rats. CONCLUSION: GLP-2 is secreted from the intestine in response to intestinal injury, probably explaining the compensatory hyperproliferation after chemotherapy. Exogenous GLP-2 can protect the mucosa from chemotherapy-induced mucositis in rats.

AB - PURPOSE: Gastrointestinal mucositis is an unwanted and often dose-limiting side effect to most cancer treatments. Glucagon-like peptide-2 (GLP-2) is a peptide secreted from intestinal L-cells in response to nutrient intake. The peptide is involved in the regulation of apoptosis and proliferation in the intestine. We aimed to investigate the role of GLP-2 in experimental chemotherapy-induced mucositis. METHODS STUDY 1: Rats were given a single injection with 5-fluorouracil (5-FU) and killed in groups of five each day for 5 days. Blood samples were analysed for GLP-2 concentrations. The intestine was analysed for weight loss, morphometric estimates and proliferation. Study 2 Rats were treated with GLP-2 or control vehicle 2 days before a single injection of 5-FU or saline. The treatments continued until kill 2 days after. The intestine was investigated for influx of myeloperoxidase (MPO)-positive cells and morphometric estimates, such as villus height, as a marker of mucositis. RESULTS STUDY 1: Two days after chemotherapy, there was a rise in endogenous GLP-2, followed by a marked increase in proliferation. Study 2 Exogenous GLP-2 was able to protect the intestine from severe weight loss and completely prevented the reduction in villus height in the control rats. Furthermore, there was a significant decrease in influx of MPO-positive cells in the GLP-2-treated rats. CONCLUSION: GLP-2 is secreted from the intestine in response to intestinal injury, probably explaining the compensatory hyperproliferation after chemotherapy. Exogenous GLP-2 can protect the mucosa from chemotherapy-induced mucositis in rats.

U2 - 10.1007/s00280-012-1882-2

DO - 10.1007/s00280-012-1882-2

M3 - Journal article

VL - 70

SP - 39

EP - 48

JO - Cancer Chemotherapy and Pharmacology. Supplement

JF - Cancer Chemotherapy and Pharmacology. Supplement

SN - 0943-9404

IS - 1

ER -

ID: 38531176